These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 29475935)

  • 1. Prognostic Impact of Inflammation-related Biomarkers on Overall Survival of Patients with Inoperable Malignant Pleural Mesothelioma.
    Otoshi T; Kataoka Y; Kaku S; Iki R; Hirabayashi M
    In Vivo; 2018; 32(2):445-450. PubMed ID: 29475935
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relation between neutrophil/lymphocyte ratio and primary tumor metabolic activity in patients with malign pleural mesothelioma.
    Özyürek BA; Özmen Ö; Özdemirel TŞ; Erdoğan Y; Kaplan B; Kaplan T
    Clin Respir J; 2018 Feb; 12(2):646-651. PubMed ID: 27768834
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stratification of malignant pleural mesothelioma prognosis using recursive partitioning analysis.
    Suzuki H; Asami K; Hirashima T; Okamoto N; Yamadori T; Tamiya M; Morishita N; Shiroyama T; Takeoka S; Osa A; Azuma Y; Okishio K; Kawaguchi T; Atagi S; Kawase I
    Lung; 2014 Feb; 192(1):191-5. PubMed ID: 24141556
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic factors and treatment outcomes of malignant pleural mesothelioma in Eastern Asian patients - A Taiwanese study.
    Wu TH; Lee LJ; Yuan CT; Chen TW; Yang JC
    J Formos Med Assoc; 2019 Jan; 118(1 Pt 2):230-236. PubMed ID: 29709339
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The C-Reactive Protein/Albumin Ratio is a Novel Significant Prognostic Factor in Patients with Malignant Pleural Mesothelioma: A Retrospective Multi-institutional Study.
    Takamori S; Toyokawa G; Shimokawa M; Kinoshita F; Kozuma Y; Matsubara T; Haratake N; Akamine T; Hirai F; Seto T; Tagawa T; Takenoyama M; Ichinose Y; Maehara Y
    Ann Surg Oncol; 2018 Jun; 25(6):1555-1563. PubMed ID: 29500763
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pretreatment serum C-reactive protein levels predict benefit from multimodality treatment including radical surgery in malignant pleural mesothelioma: a retrospective multicenter analysis.
    Ghanim B; Hoda MA; Winter MP; Klikovits T; Alimohammadi A; Hegedus B; Dome B; Grusch M; Arns M; Schenk P; Pohl W; Zielinski C; Filipits M; Klepetko W; Berger W
    Ann Surg; 2012 Aug; 256(2):357-62. PubMed ID: 22750759
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic significance of the lymphocyte-to-monocyte ratio in patients with malignant pleural mesothelioma.
    Yamagishi T; Fujimoto N; Nishi H; Miyamoto Y; Hara N; Asano M; Fuchimoto Y; Wada S; Kitamura K; Ozaki S; Kishimoto T
    Lung Cancer; 2015 Oct; 90(1):111-7. PubMed ID: 26259877
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma Biomarker Enrichment of Clinical Prognostic Indices in Malignant Pleural Mesothelioma.
    Pass HI; Goparaju C; Espin-Garcia O; Donington J; Carbone M; Patel D; Chen Z; Feld R; Cho J; Gadgeel S; Wozniak A; Chachoua A; Leighl N; Tsao MS; de Perrot M; Xu W; Liu G
    J Thorac Oncol; 2016 Jun; 11(6):900-9. PubMed ID: 26903362
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The homeobox gene EMX2 is a prognostic and predictive marker in malignant pleural mesothelioma.
    Giroux Leprieur E; Hirata T; Mo M; Chen Z; Okamoto J; Clement G; Li H; Wislez M; Jablons DM; He B
    Lung Cancer; 2014 Sep; 85(3):465-71. PubMed ID: 25023662
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Contemporary Analysis of Prognostic Factors in Patients with Unresectable Malignant Pleural Mesothelioma.
    Billé A; Krug LM; Woo KM; Rusch VW; Zauderer MG
    J Thorac Oncol; 2016 Feb; 11(2):249-55. PubMed ID: 26845118
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum albumin as a significant prognostic factor in patients with malignant pleural mesothelioma.
    Yao ZH; Tian GY; Yang SX; Wan YY; Kang YM; Liu QH; Yao F; Lin DJ
    Tumour Biol; 2014 Jul; 35(7):6839-45. PubMed ID: 25051913
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disparities in Compliance With National Guidelines for the Treatment of Malignant Pleural Mesothelioma.
    Espinoza-Mercado F; Borgella JD; Berz D; Alban RF; Sarkissian A; Imai HTA; Soukiasian HJ
    Ann Thorac Surg; 2019 Sep; 108(3):889-896. PubMed ID: 31004585
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inflammation-based prognostic indices in malignant pleural mesothelioma.
    Pinato DJ; Mauri FA; Ramakrishnan R; Wahab L; Lloyd T; Sharma R
    J Thorac Oncol; 2012 Mar; 7(3):587-94. PubMed ID: 22307011
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Value of COX-2, NF-κB, and Blood Routine Indexes in the Prognosis of Malignant Peritoneal Mesothelioma.
    Yin W; Zheng G; Su S; Liang Y
    Oncol Res Treat; 2019; 42(6):334-341. PubMed ID: 31063993
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors associated with survival in a large series of patients with malignant pleural mesothelioma in New South Wales.
    Linton A; Pavlakis N; O'Connell R; Soeberg M; Kao S; Clarke S; Vardy J; van Zandwijk N
    Br J Cancer; 2014 Oct; 111(9):1860-9. PubMed ID: 25188323
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating complement component 4d (C4d) correlates with tumor volume, chemotherapeutic response and survival in patients with malignant pleural mesothelioma.
    Klikovits T; Stockhammer P; Laszlo V; Dong Y; Hoda MA; Ghanim B; Opitz I; Frauenfelder T; Nguyen-Kim TDL; Weder W; Berger W; Grusch M; Aigner C; Klepetko W; Dome B; Renyi-Vamos F; Oehler R; Hegedus B
    Sci Rep; 2017 Nov; 7(1):16456. PubMed ID: 29184132
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Persistent lung expansion after pleural talc poudrage in non-surgically resected malignant pleural mesothelioma.
    Rena O; Boldorini R; Papalia E; Mezzapelle R; Baietto G; Roncon A; Casadio C
    Ann Thorac Surg; 2015 Apr; 99(4):1177-83. PubMed ID: 25669666
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic factors affecting survival in malignant pleural mesothelioma: analysis of 125 subjects.
    Komurcuoglu B; Cirak AK; Kirakli SC; Polat G; Yucel N; Usluer O; Erer O; Balci G; Gayaf M; Guldaval F; Aktogu S; Guclu S; Ozsoz A; Halilcolar H
    Tumori; 2014; 100(1):55-9. PubMed ID: 24675492
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survival results in biphasic malignant pleural mesothelioma patients: A multicentric analysis.
    Lococo F; Torricelli F; Lang-Lazdunski L; Veronesi G; Rena O; Paci M; Casadio C; Piana S; Novellis P; Di Stefano TS; Ciarrocchi A; Billè A
    J Thorac Cardiovasc Surg; 2020 Apr; 159(4):1584-1593.e2. PubMed ID: 31590954
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Existing models, but not neutrophil-to-lymphocyte ratio, are prognostic in malignant mesothelioma.
    Meniawy TM; Creaney J; Lake RA; Nowak AK
    Br J Cancer; 2013 Oct; 109(7):1813-20. PubMed ID: 23982605
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.